Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy [...]
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
JPM22, Day 4: Vertex aims to be cystic fibrosis leader [...]
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex’s cystic fibrosis dominance
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; [...]
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out [...]
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new drugs; Roche launches smart, point-of-care glucose monitor
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new [...]
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor
JPM22, Day 3: Intellia, Editas plan to double down on [...]
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson’s field
Sanofi makes $75M preclinical bet to join Roche, Novartis and [...]
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development
Daiichi axes 60-person Plexxikon R&D facility in California to free [...]
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND
Regeneron, 2seventy name the target of their first solid tumor [...]
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices [...]